SCHEMBL15049067

SCHEMBL15049067

CCOC(=O)c1sc(-c2ccc(-c3ccccc3C(F)(F)F)cc2)nc1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
HSP90AA1 P07900 1/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
CDC7 O00311 10/20 0.49
DBF4 Q9UBU7 10/20 0.49
TRPM8 Q7Z2W7 6/20 0.49
RARA P10276 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15048997 0.92 MEN1 (0.52) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL6336462 0.89 CDC7 (0.61) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL15049083 0.86 TRPM8 (0.60) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL15048987 0.85 TRPM8 (0.63) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL15049133 0.84 TRPM8 (0.61) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL5237288 0.83 CDC7 (0.68) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL15049377 0.83 MAPT (0.72) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL15049533 0.80 TRPM8 (0.66) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL5234021 0.80 CDC7 (0.67) MAPTMEN1KMT2AKDM4EHSP90AA1
SCHEMBL9852615 0.79 TRPM8 (0.59) MAPTMEN1KMT2AKDM4EHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 EP disclosed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 US disclosed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 US disclosed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 US disclosed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 US disclosed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 EP disclosed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 WO disclosed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129881-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM5 MAPT 282/4885MEN1 1269/4885KMT2A 1792/4885
US-20140371276-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPV1 MAPT 293/4885MEN1 1013/4885KMT2A 2307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.